Why the study?
Endomyocardial fibrosis is a restrictive cardiomyopathy of unknown etiology that carries high morbidity and mortality, requiring review of its diagnosis and management.
Design
Review
Key result
Endomyocardial fibrosis is a restrictive cardiomyopathy with a poor prognosis, where the duration of illness from presentation to death is less than one year in 43.5% of patients.
Authors
Loading...
EMF carries high morbidity/mortality in young African females; leaves open etiology, diagnostics, and optimal therapies.
Endomyocardial fibrosis is a restrictive cardiomyopathy of unknown etiology with a poor prognosis, primarily affecting young populations in tropical regions, where echocardiography is the gold standard for diagnosis.
Siddiq Ibrahim Khalil (2020) conducted a review in Endomyocardial Fibrosis. Endomyocardial fibrosis is a restrictive cardiomyopathy with a poor prognosis, where the duration of illness from presentation to death is less than one year in 43.5% of patients.